TOMOKAZU KAWAOKA

Last Updated :2026/07/06

Affiliations, Positions
Hiroshima University Hospital, Associate Professor/Lecturer
E-mail
kawaokatomohiroshima-u.ac.jp

Basic Information

Academic Degrees

  • Doctor of Philosophy in Medical Science, Hiroshima University

Research Fields

  • Medicine,dentistry, and pharmacy;Clinical internal medicine;Gastroenterology

Educational Activity

Course in Charge

  1. 2026, Undergraduate Education, Year, Clinical diagnosis and treatment I
  2. 2026, Graduate Education (Master's Program) , Second Semester, General Clinical Medicine and Dentistry
  3. 2026, Graduate Education (Doctoral Program) , 1Term, Practice of Oncology

Research Activities

Invited Lecture, Oral Presentation, Poster Presentation

  1. Patterns of Physical Activity (PA) Measured by Wearable Devices During Treatment with Atezolizumab Plus Bevacizumab (Atezo+Bev) in Japanese Patients (pts) with Unresectable Hepatocellular Carcinoma (uHCC): Results from the ELIXIR Study2025, Tomokazu Kawaoka, Tatsuya Yamashita, Michihisa Moriguchi, Atsushi Hiraoka, Masafumi Ikeda, Naoki Morimoto, Kaoru Tsuchiya, Hidenari Nagai, Ryotaro Sakamori, Shinichiro Nakamura, Keiji Tsuji, Masatoshi Kudo, Masahito Shimizu, Hidekatsu Kuroda, Norihiro Kokudo, Junji Furuse, Masaru Harada, Takahiro Yamasaki, Kouji Yamamoto, Tetsuo Takehara, ESMO, 2025/10/21, Without Invitation, English, published
  2. Prospective Observational Study on Systemic Therapy for Unresectable Hepatocellular Carcinoma (PRISM Study): An Update Analysis of First 1,000 patients., Tomokazu Kawaoka, Masafumi Ikeda, Shinji Itoh, Daisuke Onozuka, Sadahisa Ogasawara, Takashi Niizeki, Taro Yamashita, Yasuhito Tanaka, Tomoharu Yamada, Kazushi Numata, Ryosuke Tateishi, Tatsuya Yamashita, Takuji Okusaka, Junji Furuse, Masatoshi Kudo, The 15th Asia-Pacific Primary Liver Cancer Expert Meeting., 2025/07/11, Without Invitation, English, published
  3. Tumor Marker Prediction of Response to Durvalumab and Tremelimumab in Combination Therapy for Unresectable Hepatocellular Carcinoma., 2025/04/24, Without Invitation, English, published
  4. Stereotactic body radiation therapy combined with transcatheter arterial chemotherapy, APASL STC, 2018/05/11, Without Invitation, English, published
  5. Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma., 2016/11/11, Without Invitation, English, published
  6. Efficacy and safety of stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma., The 12th JSH Single Topic Conference, 2016/09/22, Without Invitation, English, published
  7. 日本超音波医学会第52回中国地方会学術集会第15回中国地方会講習会, Without Invitation, Japanese, published
  8. Hepatocellular carcinoma development in hepatitis C virus patients who achieved sustained viral response by interferon therapy and direct anti-viral agent therapy, The 12th JSH Single Topic Conference, 2016/09/22, Without Invitation, English, published
  9. Involvement of type 4 porphyromonas gingivalis in the progression of non-alcoholic fatty liver diseas, AASLD, 2016/11/11, Without Invitation, English, published
  10. "Comparison of 18F-FDG PET-CT and Gd-EOB-DTPA-enhanced MRI for prediction of microvascular invasion and outcome after curative resection for early-stage hepatocellular carcinoma ", AASLD, 2016/11/11, Without Invitation, English, published
  11. "Hepatocellular carcinoma development in hepatitis C virus patients who achieved sustained viral response by interferon therapy and direct anti-viral agents therapy ", AASLD, 2016/11/11, Without Invitation, English, published
  12. 進行肝細胞癌に対するソラフェニブ治療不応例の検討, 2017/10/16, Without Invitation, Japanese, preprint

Social Activities

History as Peer Reviews of Academic Papers

  1. 2025, Internal Medicine, Others
  2. 2025, Journal of Gastroenterology, Others
  3. 2025, Clinical Journal of Gastroenterology, Others
  4. 2017, Hepatology Research, Others